EP0576914A2 - 14-Désoxy-14-alpha-cardénolied-3-bèta-thiodérivés et compositions pharmaceutiques les contenant pour le traitement des troubles cardiovasculaires - Google Patents
14-Désoxy-14-alpha-cardénolied-3-bèta-thiodérivés et compositions pharmaceutiques les contenant pour le traitement des troubles cardiovasculaires Download PDFInfo
- Publication number
- EP0576914A2 EP0576914A2 EP93109611A EP93109611A EP0576914A2 EP 0576914 A2 EP0576914 A2 EP 0576914A2 EP 93109611 A EP93109611 A EP 93109611A EP 93109611 A EP93109611 A EP 93109611A EP 0576914 A2 EP0576914 A2 EP 0576914A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- card
- enolide
- pyrrolidinyl
- dienolide
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 C[C@](CC1)([C@](CC2)C(CC3C4)C1[C@@](C)(CC1)C3[C@@]4[C@@]1S*)[C@]2C(CO1)=CC1=O Chemical compound C[C@](CC1)([C@](CC2)C(CC3C4)C1[C@@](C)(CC1)C3[C@@]4[C@@]1S*)[C@]2C(CO1)=CC1=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
Definitions
- the present invention relates to 14-deoxy-14a-cardenolide 3,8 -thioderivatives, a process for their preparation and pharmaceutical compositions containing same for the treatment of cardiovascular disorders such as heart failure and hypertension.
- the invention includes within its scope all the possible stereoisomers, in particular E and Z isomers, optical isomers and their mixtures and the metabolites and the metabolic precursors of the compounds of formula (I).
- E and Z isomers in particular E and Z isomers, optical isomers and their mixtures and the metabolites and the metabolic precursors of the compounds of formula (I).
- # is a single bond both the 5a and 5,8 isomers are encompassed within the scope of the present invention.
- compositions of (I) are salts which retain the biologically activity of the base and are derived from such known pharmacologically accetable acids such as e.g. hydrochloric, sulfuric, phosphoric, malic, tartaric, maleic, citric, methanesulfonic or benzoic acid.
- the alkyl and alkenyl groups may be branched or straight chain groups.
- the C2-C6 alkyl group is preferably a C2-C4 alkyl group, e.g. ethyl, propyl, isopropyl, butyl, sec-butyl.
- the C3-C6 alkenyl group is preferably a C3-C4 alkenyl group.
- the quaternary ammonium group is preferably a trimethylammonium- or a N-methylpyrrolidinium- or a N-methylpiperidinium- group.
- the OR1 group is preferably hydroxy, 2-aminoethoxy, 3-aminopropoxy, 2-dimethylaminoethoxy, 3-dimethylaminopropoxy, 3-amino-2-hydroxypropoxy, 2,3-diaminopropoxy, 2-(1-pyrrolidinyl)ethoxy,3-(1-pyrrolidinyl)propoxy.
- the NR2R3 group is preferably amino, methylamino, ethylamino, propylamino, isopropylamino, allylami- no, propargylamino, dimethylamino, pyrrolidinyl, morpholino, piperazinyl, imidazolyl, guanidino, 2-aminoethylamino, 3-aminopropylamino, 2-(1-pyrrolidinyl)ethylamino, 3-(1-pyrrolidinyl)propylamino.
- the C(NH)NR4R5 group is preferably a primary amidino group.
- the NR6R7 is preferably amino, methylamino, ethylamino, propylamino, dimethylamino, pyrrolidinyl, morpholino, piperazinyl or imidazolyl.
- Preferred examples of specific compounds according to the present invention are:
- the invention furthermore provides a process for the preparation of said compounds (I), which comprises condensing the compounds having formula (II) where '" is as above defined with a compound of formula (III) where Y is an electron-withdrawing group, such as halogen, mesyloxy, or tosyloxy group, which confers electrophilic properties to the attached carbon atom, and R is as above defined, the hydroxy and amino groups, if any, present in R being protected, if necessary, with methods well known to those skilled in the art to give, after removal of the protective groups, if any, compounds of general formula (I) which may be converted into other compounds of formula (I) and optionally converting compounds (I) into pharmaceutically acceptable salts thereof and optionally separating a mixture of isomers into single isomers.
- Y is an electron-withdrawing group, such as halogen, mesyloxy, or tosyloxy group, which confers electrophilic properties to the attached carbon atom
- R is as above defined, the
- condensation reaction between (II) and (III) is best carried out in an inert aprotic solvent, such as tetrahydrofuran, dioxane, dimethylformamide, dimethylsulfoxyde or in the neat (III) and in the presence of a strong base e.g. sodium or potassium hydride at a temperature ranging from -20 ° C to about 60 °C.
- an inert aprotic solvent such as tetrahydrofuran, dioxane, dimethylformamide, dimethylsulfoxyde
- the purifications are best performed by flash-chromatography on silica gel.
- acetylthio derivatives (IV) are new and are obtained by reaction of the 3a-alcohols (V) with thiolacetic acid in the presence of a dialkyl azodicarboxylate and triphenylphosphine.
- the intermediate 3-oxo-14a-card-4,20(22)-dienolide (formula (VI) wherein --- is a double bond in position 4) is a known compound (Fritsch W. et al., Liebigs Ann. Chem. 1966, 699, 195).
- the 3-oxo-14a-card-5,20(22)-dienolide (formula (VI) wherein ---- is a double bond in position 5; see Prep. 12) is a new compound and is obtained by oxidation of the corresponding known 3,8-hydroxy derivative (Fritsch W. et al., Liebigs Ann. Chem. 1966, 699, 195) with morpholine-N-oxide in the presence of a perruthenate salt.
- the 3-oxo-5a,14a-card-20(22)-enolide (formula (VI) wherein ---- are single bonds and the hydrogen in position 5 is a; see Prep. 13) is a new compound and is obtained by oxidation of the corresponding known 3,8-hydroxy derivative (Kreiser W. and Vietnameser M., Liebigs Ann. Chem. 1972, 755, 1) with morpholine-N-oxide in the presence of a perruthenate salt.
- the compounds of general formula (III) are known compounds, generally commercially available or preparable from known compounds by known methods
- the 14-deoxy-14a-derivatives of digitoxigenin was expected from the literature data (Naidoo B.K., et al., J. Pharm. Sciences, 1974, 63, 1391) to be practically devoid of inotropic effect; however, unexpectedly, the thioderivatives (I), prepared according to the invention and their pharmaceutically acceptable salts are useful agents for the treatment of cardiovascular disorders such as heart failure and hypertension and have low toxicity. Moreover said compounds (I) show high affinity for the receptor site of the Na + ,K +- ATPase and behave as partial agonists on the enzymatic activity of the Na + ,K +- ATPase.
- DIGI aglycone digitoxigenin
- the solution was refluxed under nitrogen atmosphere for 3 hrs, then 5 ml of water were added and the resulting mixture extracted with methylene chloride. The organic layer was dried over sodium sulfate and evaporated to dryness under reduced pressure.
- the crude product was purified by flash-cromatography (Si0 2 ) using methylene chloride/methanol/30%ammonia solution 95/5/1 as eluant; the pure compound so obtained was dissolved in 2 ml of diethyl ether and a solution of 0.080 g of oxalic acid in 1 ml of diethyl ether was added to give 0.31 g of the title compound (I-a) as a white solid, mp 164-166 °C.
- the crude product was purified by flash-chromatography (Si0 2 ) using n-hexane/ethyl acetate 60/40 as eluant to give 0.30 g of 3 ⁇ -(2,3-epoxy)propylthio-5 ⁇ ,14 ⁇ -card-20(22)-enolide as a white pasty solid.
- Diisopropyl azodicarboxylate (7.7 ml) was added to a solution of 10.3 g of triphenylphosphine in 160 ml of tetrahydrofuran and the mixture was stirred for 30'. A white precipitate formed.
- a solution of 5.6 g of 3a-hydroxy-5 ⁇ ,14 ⁇ -card-20(22)-enolide and 2.8 ml of thiolacetic acid in 160 ml of tetrahydrofuran was added dropwise and the resulting mixture was stirred for 2 hrs at room temperature.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4221538A DE4221538C1 (de) | 1992-07-01 | 1992-07-01 | 14-Desoxy-14alpha-cardenolid-3beta-thioderivate |
DE4221538 | 1992-07-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0576914A2 true EP0576914A2 (fr) | 1994-01-05 |
EP0576914A3 EP0576914A3 (fr) | 1995-04-19 |
Family
ID=6462209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP93109611A Ceased EP0576914A3 (fr) | 1992-07-01 | 1993-06-16 | 14-Désoxy-14-alpha-cardénolied-3-bèta-thiodérivés et compositions pharmaceutiques les contenant pour le traitement des troubles cardiovasculaires. |
Country Status (4)
Country | Link |
---|---|
US (1) | US5489582A (fr) |
EP (1) | EP0576914A3 (fr) |
JP (1) | JPH0733795A (fr) |
DE (1) | DE4221538C1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0742214A1 (fr) * | 1995-05-11 | 1996-11-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Séco-D-stéroides actifs sur le système cardiovasculaire et compositions pharmaceutiques les contenant |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3268520A (en) * | 1963-01-23 | 1966-08-23 | Bayer Ag | Steroid guanylhydrazones and production thereof |
FR1491081A (fr) * | 1965-09-01 | 1967-08-04 | Hoechst Ag | Lactones non saturées de la série des stéroïdes et leur préparation |
FR1555396A (fr) * | 1967-03-10 | 1969-01-24 | ||
FR2100872A1 (fr) * | 1970-07-07 | 1972-03-24 | Hoechst Ag |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1038294A (fr) * | 1975-04-14 | 1978-09-12 | American Home Products Corporation | Methode et composes pour abaisser la pression intraoculaire |
DE2517293C2 (de) * | 1975-04-18 | 1984-02-16 | Knoll Ag, 6700 Ludwigshafen | Neue Cardenolid-β-Glykoside, ihre Herstellung und Verwendung |
FR2310766A1 (fr) * | 1975-05-16 | 1976-12-10 | Nativelle Sa Ets | Derives de cardenolides, procede de preparation et application a titre de medicament |
DE2833472A1 (de) * | 1978-07-29 | 1980-03-06 | Beiersdorf Ag | Digitoxigenin-monodigitoxosid-derivate und verfahren zu ihrer herstellung |
US4259240A (en) * | 1979-09-28 | 1981-03-31 | Advance Biofactures Corporation | Synthesis of furyl intermediates, and cardenolides and their isomers prepared therefrom |
-
1992
- 1992-07-01 DE DE4221538A patent/DE4221538C1/de not_active Expired - Fee Related
-
1993
- 1993-06-16 EP EP93109611A patent/EP0576914A3/fr not_active Ceased
- 1993-06-24 US US08/080,525 patent/US5489582A/en not_active Expired - Fee Related
- 1993-06-30 JP JP5161311A patent/JPH0733795A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3268520A (en) * | 1963-01-23 | 1966-08-23 | Bayer Ag | Steroid guanylhydrazones and production thereof |
FR1491081A (fr) * | 1965-09-01 | 1967-08-04 | Hoechst Ag | Lactones non saturées de la série des stéroïdes et leur préparation |
FR1555396A (fr) * | 1967-03-10 | 1969-01-24 | ||
FR2100872A1 (fr) * | 1970-07-07 | 1972-03-24 | Hoechst Ag |
Non-Patent Citations (1)
Title |
---|
JOURNAL OF PHARMACEUTICAL SCIENCES, vol.63, no.9, September 1974, WASHINGTON US pages 1391 - 1394 Naidoo B K et al 'Cardiotonic steroids. I. Importance of 14.beta.-hydroxy group in digitoxigenin' * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0742214A1 (fr) * | 1995-05-11 | 1996-11-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Séco-D-stéroides actifs sur le système cardiovasculaire et compositions pharmaceutiques les contenant |
Also Published As
Publication number | Publication date |
---|---|
US5489582A (en) | 1996-02-06 |
EP0576914A3 (fr) | 1995-04-19 |
DE4221538C1 (de) | 1994-03-31 |
JPH0733795A (ja) | 1995-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4975537A (en) | Δ9(11) -angiostatic steroids | |
KR860000452B1 (ko) | 소염작용을 갖는 연성 스테로이드의 제조방법 | |
US5914324A (en) | 6-Hydroxy and 6-oxo-androstane derivatives active on the cardiovascular system and pharmaceutical compositions containing same | |
JPH07316187A (ja) | 11,21−ビスフェニル−19−ノルプレグナン誘導体 | |
EP0413270A2 (fr) | 17-bêta-(cyclopropyl-amino)-androst-5-en-3-bêta-ol,substitué en position 4 et ses derivés- utilisables comme inhibiteurs de C17-20 lyase | |
EP0583578B1 (fr) | 17B(3-furyle) et 17B(4-pyridazinyle)-5béta, 14béta-androstanes cardioactifs, procédé pour leur préparation et les compositions pharmaceutiques les renfermant | |
US5593982A (en) | Cyclopentanperhydrophenanthren-17β-(3-furyl)-3-derivatives and pharmaceutical compositions comprising same for the treatment of cardiovascular disorders | |
EP0106453B1 (fr) | Esters de 21-hydroxy-corticostéroides et compositions les contenant | |
FI87791B (fi) | Foerfarande foer framstaellning av 17 -(cyklopropyloxi)androst-5-en-3 -ol och naerstaoende foereningar, som aer anvaendbara som c17-20 lyas inhibitorer | |
EP0221705A1 (fr) | Tétrahydro-stéroides à activité angiostatique | |
EP0742214B1 (fr) | Séco-D-stéroides actifs sur le système cardiovasculaire et compositions pharmaceutiques les contenant | |
US5489582A (en) | 14-deoxy-14α-cardenolides 3β-thioderivatives and pharmaceutical composition comprising same for treating cardiovascular disorders | |
US5478817A (en) | Digitoxigenin and dihydrodigitoxigenin 3β-derivatives and pharmaceutical compositions comprising same for the treatment of cardiovascular disorders | |
EP0231671B1 (fr) | Gonatriènes et procédé pour les préparer | |
EP0590489B1 (fr) | Nouveaux dérivés cyclopentaperhydrophenanthrene-17-bêta-(hydroxy ou alkoxy)-17-alpha-(aryle ou héterocyclyle)-3 bêta cardioactivs, un procédé pour leur préparation et les compositions pharmaceutiques les contenant | |
JP3293629B2 (ja) | 新規なオキサ又はアザステロイド7位置換化合物 | |
US5705662A (en) | 17-(3-imino-2-alkylpropenyl)-5β, 14β-androstane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same | |
Aristoff et al. | Δ 9 (11)-angiostatic steroids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17P | Request for examination filed |
Effective date: 19950626 |
|
17Q | First examination report despatched |
Effective date: 19951012 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
K1C1 | Correction of patent application (title page) published |
Effective date: 19940105 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 19970804 |